Evaluation of Dual-hormone Artificial Pancreas With Closed-loop Glucose Control Versus Single-hormone With Carbohydrate Recommendations Under Unannounced Exercise and Meal Challenge in Adults With Type 1 Diabetes.
The trial, sponsored by Universitat Politècnica de València, evaluates a dual-hormone artificial pancreas system against a single-hormone configuration in adults with Type 1 Diabetes (T1D). The dual-hormone approach aims to reduce hypoglycemic events and improve time in target glucose range, addressing a significant unmet need in diabetes management. The market for diabetes management technologies is expanding, with increasing adoption of automated insulin delivery systems. Successful outcomes could position the dual-hormone system as a competitive alternative to existing single-hormone systems, potentially enhancing patient adherence and outcomes. Companies in the diabetes technology space should monitor this trial closely for implications on product development and market positioning.
Indication: Type 1 Diabetes
Modality: medical device
Target: Dual-hormone artificial pancreas system utilizing insulin and glucagon for glucose control in Type 1 Diabetes management.
Sponsor: Universitat Politècnica de València
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 08, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Dual-hormone artificial pancreas system utilizing insulin and glucagon for glucose control in Type 1 Diabetes management.
View original source fields
Condition raw: Type 1 Diabetes
Condition normalized: Type 1 Diabetes
Modality raw: medical device
Modality normalized: medical device
Target raw: Dual-hormone artificial pancreas system utilizing insulin and glucagon for glucose control in Type 1 Diabetes management.
Target normalized: Dual-hormone artificial pancreas system utilizing insulin and glucagon for glucose control in Type 1 Diabetes management.